Status:

COMPLETED

The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study

Lead Sponsor:

AstraZeneca

Conditions:

Hypercholesterolemia

Eligibility:

All Genders

50-80 years

Phase:

PHASE3

Brief Summary

To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)

Eligibility Criteria

Inclusion

  • Signed informed consent, between 50 and 80 years of age, end stage renal failure patients receiving hemodialysis

Exclusion

  • Received statins within past 6 months, a clear indication for use of lipid altering drug, contra indication for lipid altering drug, history of statin induced myopathy items in very

Key Trial Info

Start Date :

January 1 2003

Trial Type :

INTERVENTIONAL

End Date :

October 1 2008

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT00240279

Start Date

January 1 2003

End Date

October 1 2008

Last Update

November 19 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Research Site

Nieuwegein, Netherlands

The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study | DecenTrialz